<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941833</url>
  </required_header>
  <id_info>
    <org_study_id>147/2564</org_study_id>
    <nct_id>NCT04941833</nct_id>
  </id_info>
  <brief_title>Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo</brief_title>
  <official_title>The Use of Oral Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo : A Randomized Controlled Trial Evaluation of the Effect on Cyst Diameter and Associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of the oral desogestrel compared with placebo for preoperative treatment of endometrioma&#xD;
      in the patient who underwent to surgery in next 3 months The result will be evaluated on cyst&#xD;
      diameter, the associated pain and side effect of the oral desogestrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of the oral desogestrel compared with placebo for preoperative treatment of endometrioma&#xD;
      in the patient who underwent to surgery in next 3 months in Rajvithi hospital Patient will&#xD;
      randomized in 2 group : Desogestrel and placebo After 1 months and 3 months the patient have&#xD;
      to come to hospital to evaluate the result of study The result will be evaluated on cyst&#xD;
      diameter, the associated pain and side effect of the oral desogestrel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cyst diameter</measure>
    <time_frame>3 months after drug given</time_frame>
    <description>Cyst diameter is calculated by transvaginal ultrasound with calculated in the diameter of endometrimas (cm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associated pain</measure>
    <time_frame>3 months after drug given</time_frame>
    <description>Associated pain is measured by the visual analog score. The patients will record the score on the book everytimes when they have pain</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of the drug in the study</measure>
    <time_frame>3 months after drug given</time_frame>
    <description>Effect of the oral desogestrel and placebo such as spotting, weight gain, wood swing</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Endometrioma</condition>
  <arm_group>
    <arm_group_label>Desogestrel group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desogestrel group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogestrel Oral Tablet</intervention_name>
    <description>Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Desogestrel group</arm_group_label>
    <other_name>Cerazette</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Thai female and foreigner who can understand Thai language&#xD;
&#xD;
          -  Age 15-49 years&#xD;
&#xD;
          -  Diagnose as endometrioma sized more than 3 cm&#xD;
&#xD;
          -  Underwent to surgery in next 13 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of endometriosis&#xD;
&#xD;
          -  Pregnancy woman&#xD;
&#xD;
          -  Contraindication for desogestrel : History of thrombotic event, Autoimmune&#xD;
             disease,gestational trophoblastic disease&#xD;
&#xD;
          -  Ovarian endometrioma with complications : Ruptured, twisted&#xD;
&#xD;
          -  Contraindications for NSAIDs : Peptic ulcer, thrombocytopenia, liver disease&#xD;
&#xD;
          -  History of hormonal treatment for endometrioma : DMPA,OCP, GNRH agonist/antoginist&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ratchadaporn Roekyindee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rajavithi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atitaya Sakunthai, MD</last_name>
    <phone>0896224462</phone>
    <email>A.sakunthai@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ratchadaporn Roekyindee, Subspecialty</last_name>
      <phone>081-5766202</phone>
      <email>Ratchadaporn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Atitaya Sakunthai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>https://www.tandfonline.com/doi/full/10.1080/09513590.2017.1296124?scroll=top&amp;needAccess=true</url>
    <description>Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial</description>
  </link>
  <link>
    <url>https://journals.sagepub.com/doi/full/10.5301/je.5000219</url>
    <description>Long-Term Administration of Dienogest Reduces Recurrence after Excision of Endometrioma</description>
  </link>
  <reference>
    <citation>Muzii L, Galati G, Di Tucci C, Di Feliciantonio M, Perniola G, Di Donato V, Benedetti Panici P, Vignali M. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol. 2020 Jan;36(1):81-83. doi: 10.1080/09513590.2019.1640199. Epub 2019 Jul 14.</citation>
    <PMID>31304853</PMID>
  </reference>
  <reference>
    <citation>Cucinella G, Granese R, Calagna G, Svelato A, Saitta S, Tonni G, De Franciscis P, Colacurci N, Perino A. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference? Arch Gynecol Obstet. 2013 Oct;288(4):821-7. doi: 10.1007/s00404-013-2841-9. Epub 2013 Apr 12.</citation>
    <PMID>23580011</PMID>
  </reference>
  <reference>
    <citation>Taniguchi F, Enatsu A, Ota I, Toda T, Arata K, Harada T. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma. Eur J Obstet Gynecol Reprod Biol. 2015 Aug;191:116-20. doi: 10.1016/j.ejogrb.2015.06.006. Epub 2015 Jun 16.</citation>
    <PMID>26115056</PMID>
  </reference>
  <reference>
    <citation>Razzi S, Luisi S, Ferretti C, Calonaci F, Gabbanini M, Mazzini M, Petraglia F. Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2007 Dec;135(2):188-90. Epub 2006 Sep 11.</citation>
    <PMID>16963174</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

